CRISPR Therapeutics AG - ESG Rating & Company Profile powered by AI
Comprehensive Sustainability assessment of CRISPR Therapeutics AG are reached by logging in. The analysis of CRISPR Therapeutics AG leverages data from across the web as well as from public filings by CRISPR Therapeutics AG. Alternative corporations in the scoring industry group for CRISPR Therapeutics AG are displayed below.
CRISPR Therapeutics AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 4.0, social score of 3.0 and governance score of 3.4.
3.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1144 | Veerhealth Care Ltd | 3.6 | Medium |
| 1144 | iStreet Network Ltd | 3.6 | Medium |
| 1186 | CRISPR Therapeutics AG | 3.5 | Medium |
| 1186 | Catalent Inc | 3.5 | Medium |
| 1186 | Akero Therapeutics Inc | 3.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does CRISPR Therapeutics AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose current and historical energy intensity?
Sign up for free to unlockDoes CRISPR Therapeutics AG report the average age of the workforce?
Sign up for free to unlockDoes CRISPR Therapeutics AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose cybersecurity risks?
Sign up for free to unlockDoes CRISPR Therapeutics AG offer flexible work?
Sign up for free to unlockDoes CRISPR Therapeutics AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes CRISPR Therapeutics AG conduct supply chain audits?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes CRISPR Therapeutics AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose water use targets?
Sign up for free to unlockDoes CRISPR Therapeutics AG have careers partnerships with academic institutions?
Sign up for free to unlockDid CRISPR Therapeutics AG have a product recall in the last two years?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose incidents of discrimination?
Sign up for free to unlockDoes CRISPR Therapeutics AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas CRISPR Therapeutics AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose parental leave metrics?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes CRISPR Therapeutics AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes CRISPR Therapeutics AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs CRISPR Therapeutics AG involved in embryonic stem cell research?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose its waste policy?
Sign up for free to unlockDoes CRISPR Therapeutics AG report according to TCFD requirements?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose energy use targets?
Sign up for free to unlockDoes CRISPR Therapeutics AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes CRISPR Therapeutics AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for CRISPR Therapeutics AG
These potential risks are based on the size, segment and geographies of the company.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.